SPEAKERS FROM ALL OVER THE WORLD

 

Speaker Map

 

Karen Aiach, Founder and Chief Executive Officer, Lysogene

Einar Andreassen, Senior Adviser, Norwegian Medicines Agency

Donna Armentano, Executive Director, Global Head Gene Therapy External R&D Innovation, Pfizer, Inc

Alison Bateman House, Postdoctoral Fellow, Division of Medical Ethics,, New York University Langone Medical Center

Ms Soraya Bekkali, Senior Vice President and Chief Medical Officer, Lysogene

Stella Blackburn, Vice President, Global Head of Risk Management, Real-World Insights, QuintilesIMS

Stella Blackburn at World Orphan Drug Congress USA 2017

Paul Bolno, President and Chief Executive Officer, WaVe Life Sciences

Mr Max Bronstein, Senior Director, Public and Government Relations, EveryLife Foundation for Rare Diseases

Angela Chaves, President, FEDERACION COLOMBIANA DE ENFERMEDADES RARAS

Andrea Chiesi, Director of Research and Development and Portfolio Management, Chiesi

Ms Leah Christl, Associate Director for Therapeutic Biologics and Biosimilars, Office of New Drugs C.D.E.R. F.D.A.

Ms Leah Christl at World Orphan Drug Congress USA 2017

Margaret Collins, Pathologist, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Professor of Pediatrics,, Cincinnati Childrens Hospital

Francesca Cook, Director, Pricing and Market Access, RegenxBio

Francesca Cook at World Orphan Drug Congress USA 2017

Gregory Daniel, Deputy Director, Duke University

Peter Dehnel, Medical Director, Blue Cross and Blue Shield of Minnesota

Peter Dehnel at World Orphan Drug Congress USA 2017

Keith DeMatteo, Director, Global Procurement Center of Excellence, Bristol Myers Squibb

Kelly Du Plessis, Chief Executive Officer, Rare Disease Society of South Africa

Kelly Du Plessis at World Orphan Drug Congress USA 2017

Valerie Duquet, Clinical Team Manager, PRA Health Sciences

Valerie Duquet at World Orphan Drug Congress USA 2017

Glyn Edwards, Chief Executive Officer, Summit Therapeutics

Mary Frances Harmon, Head of Global Patient Advocacy, PTC Therapeutics

Mary Frances Harmon at World Orphan Drug Congress USA 2017

Ms Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Vignesh Ganapathy, Associate Director of Advocacy & Government Relations, EveryLife Foundation for Rare Diseases

Vignesh Ganapathy at World Orphan Drug Congress USA 2017

Chris Garabedian, Former President and Chief Executive Officer, Sarepta Therapeutics

Eric Gascho, Vice President of Government Affairs, National Health Council

Ms Deborah Geraghty, Head of Commercial and Portfolio Strategy, Dimension Therapeutics

Jayne Gershkowitz, Senior Vice President and Chief Patient Advocate, Amicus Therapeutics Inc

Michael Goettler, Global President, Pfizer Rare Disease

Jonathan Goldsmith, Associate Director Rare Diseases Program, Food And Drug Administration

Jonathan Goldsmith at World Orphan Drug Congress USA 2017

Rashmi Gopal-Srivastava, Director, Extramural Research Program, Office Rare Diseases Research, National Cnter for Advancing Translational Sciences(NCATS), National Institutes of Health

Hazel Gorham, Director of Biosimilars Development, P.R.A. Health Sciences

Hazel Gorham at World Orphan Drug Congress USA 2017

Scott Gray, Chief Executive Officer, Clincierge

Mr James Greenwood, Chief Executive Officer, Biotechnology Industry Organization

Sascha Haverfield, Senior Vice President, Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Colin Hayward, Chief Medical Officer, Premier Research

Jonathan Heller, Executive Director and Global Head, External R&D Innovation, Rare Diseases, Pfizer, Inc

Jonathan Heller at World Orphan Drug Congress USA 2017

Mrs Claudia Hirawat, Chair, EURORDIS

Kenneth Hobby, President, Cure SMA

Angus Hogg, Vice President Hunters (MPSII) Franchise, Shire Pharmaceuticals Ltd

Angus Hogg at World Orphan Drug Congress USA 2017

Kay Holcombe, Senior Vice President for Science Policy, Biotechnology Industry Organization (BIO)

Kay Holcombe at World Orphan Drug Congress USA 2017

Wills Hughes-Wilson, Senior Vice President, Chief Patient Access Officer, Sobi

Cynthia Jackson, Vice President and Head, Pediatric and Rare Disease Centers of Excellence, QuintilesIMS

Cynthia Jackson at World Orphan Drug Congress USA 2017

Donald Johns, Vice President, Head ALS Neuroscience Discovery & Development SMA Clinical Development, Vice-Chair, Clinical Trial Review Board, Biogen

Matt Kapusta, Chief Executive Officer, uniQure

Matt Kapusta at World Orphan Drug Congress USA 2017

Petra Kaufmann, Director, Office of Rare Diseases Research and Division of Clinical Innovation, National Institutes of Health

Sven Kili, Vice President and Head of Gene Therapy Development, GSK

Yann Le Cam, Chief Executive Officer, EURORDIS

Nadea Leavitt, Engagement Manager, Predictive Analytics, Real World Insights, QuintilesIMS

Nadea Leavitt at World Orphan Drug Congress USA 2017

Nick Leschly, President and Chief Executive Officer, bluebird bio

Terrie Livingston, Senior Director, US Medical, Biogen

Aoife M Brennan, Chief Medical Officer, Synlogic Therapeutics

Aoife M Brennan at World Orphan Drug Congress USA 2017

Jeffrey D. Marrazzo, Co Founder and Chief Executive Officer, Spark Therapeutics

Marc Martinell, Chief Executive Officer, Minoryx Therapeutics

Marc Martinell at World Orphan Drug Congress USA 2017

Marc Martinell, Chief Executive Officer, Minoryx Therapeutics

Howard Mayer, Senior Vice President & Head of Global Clinical Development, Shire Pharmaceuticals Inc

Andrew McFayden, Executive Director, The Isaac Foundation

Andrew McFayden at World Orphan Drug Congress USA 2017

Paul Melmeyer, Associate Director of Public Policy, National Organization for Rare Disorders

Paul Melmeyer at World Orphan Drug Congress USA 2017

Christopher Missling, President and Chief Executive Officer, Anavex Life Sciences

Christopher Missling at World Orphan Drug Congress USA 2017

Kenneth Moch, Former Chief Executive Officer, Chimerix

Richard Moscicki, Deputy Director for Science Operations, CDER, FDA

Michael Murphy, Chief Medical & Scientific Officer, Worldwide Clinical Trials

Francois Nader, Board Chairman, Acceleron Pharma (XLRN), Former President & CEO, NPS Pharmaceuticals

Yukiko Nishimura, Chief Secretariat of International Relations, Japan Patients Association, ASrid

Letitia O'dwyer, Chief Executive Officer, New Zealand Organisation For Rare Disorders

Luca Pani, Director General, Italian Medicines Agency A.I.F.A.

Nancy Parsons, Vice President Commercial Operations, Pharmaceutical Products, SigmaTau Pharmaceuticals

Nancy Parsons at World Orphan Drug Congress USA 2017

Eric Pauwels, Senior Vice President and General Manager, The Americas, PTC Therapeutics

Edmund Pezalla, Fomer Vice President of National Medical Director of Pharmaceutical Policy and Strategy, Aetna

Mr Andreas Pleil, Senior Director, Team Lead, Outcomes & Evidence Hematology Global Health & Value, Pfizer Inc

Sy Pretorius, Senior Vice President and Chief Scientific Officer, PAREXEL International

Ms Harsha Rajasimha, Co Founder, Indian Organization For Rare Diseases

Gayatri Rao JD., MD,, Director, Orphan Products Development, FDA

Jens Renstrup, SVP, Head of Global Medical Affairs, Alexion Pharmaceuticals

Jens Renstrup at World Orphan Drug Congress USA 2017

Scott Rocklage, Former CEO, Epirus Biosciences, Managing Partner, 5AM Ventures

Scott Rocklage at World Orphan Drug Congress USA 2017

Mark Rothera, Chief Commercial Officer, PTC Therapeutics

Mark Rothera at World Orphan Drug Congress USA 2017

Peter Saltonstall, CEO, National Organization For Rare Disorders

Amanda Samanek, Executive Director, Genetic and Rare Disease Network, Australia

Amanda Samanek at World Orphan Drug Congress USA 2017

Scott Schliebner, Vice President of Rare Diseases and Scientific Affairs, PRA Health Sciences

Ana Maria Serrato Navas, Country Manager, Colombia, Aegerion Pharmaceuticals

Ana Maria Serrato Navas at World Orphan Drug Congress USA 2017

Mr Thomas Sproat, Senior Vice President, Scientific Services, ClinicalMind

Mr Thomas Sproat at World Orphan Drug Congress USA 2017

Mary Szela, Chief Executive Officer, Aegerion Pharmaceuticals

Birgitte Volck, Senior Vice President, Head of R&D Rare Diseases, GSK

Mr Timothy Walbert, Chairman, President, and Chief Executive Officer, Horizon Pharma

Diane White, Assoc. Director Development Sciences Project Management, Biomarin

Diane White at World Orphan Drug Congress USA 2017

Barbara Wuebbels, Vice President of Patient Advocacy, Audentes Therapeutics

 

DOWNLOAD BROCHURE

 

INTERESTED IN SPONSORING OR EXHIBITING?

Contact Andre Singer at andre.singer@terrapinn.com
or  +1 646 619 1797